Salubris(SZ:002294) Xin Lang Zheng Quan·2025-11-10 06:24Core Insights - The stock price of Xinlitai has increased by 95.79% year-to-date, with a recent trading price of 59.58 CNY per share as of November 10 [1] - The company reported a revenue of 3.241 billion CNY for the first nine months of 2025, reflecting an 8% year-on-year growth, and a net profit of 581 million CNY, up 13.93% [2] - Xinlitai has distributed a total of 7.204 billion CNY in dividends since its A-share listing, with 1.649 billion CNY distributed over the past three years [3] Company Overview - Xinlitai Pharmaceutical Co., Ltd. is located in Shenzhen, Guangdong Province, and was established on November 3, 1998, with its stock listed on September 10, 2009 [1] - The company's main business includes the research, production, and sales of pharmaceuticals and medical devices, with revenue composition as follows: 81.69% from formulations, 8.54% from devices, 7.17% from raw materials, and 2.59% from others [1] Shareholder and Market Activity - As of September 30, 2025, Xinlitai had 25,200 shareholders, an increase of 4.87% from the previous period, with an average of 44,249 circulating shares per shareholder, down 4.64% [2] - The top ten circulating shareholders include notable funds, with China Europe Medical Health Mixed A being the second-largest shareholder, increasing its holdings by 1.0162 million shares [3]